Method for preparing pravastatin-loading vascular tissue engineering scaffold material by electrospinning

Abstract

The invention relates to a method for preparing a pravastatin-loading vascular tissue engineering scaffold material by electrospinning. The method comprises: (1) preparing a polyhydroxyalkanoate solution; (2) preparing a pravastatin sodium solution; 3) preparing an electrospinning solution; and (4) electrospinning to obtain a vascular tissue engineering scaffold material. According to the presentinvention, the hydrophilic pravastatin sodium is loaded into the hydrophobic polyhydroxyalkanoate matrix, such that the prepared vascular tissue engineering scaffold material can achieve the long-acting release of pravastatin.

Description

technical field [0001] The invention relates to a prosthetic material, in particular to a fibrous artificial blood vessel material loaded with statin drugs. Background technique [0002] With the development of society and economy, cardiovascular disease has become the leading cause of death for human beings, and the annual treatment costs related to cardiovascular disease are huge. At present, the clinical surgical treatment of vascular diseases often uses autologous transplantation, allogeneic or xenografting, and artificial materials for vascular reconstruction. However, the supply of autologous transplantation is insufficient, and allogeneic or xenografting is prone to rejection infection or ethical issues, and the current artificial materials are not available. It has physiological functions and is prone to problems such as stenosis, embolism, calcium deposition or infection. [0003] In tissue engineering, autologous cells are planted on degradable scaffold materials ...

AI Technical Summary

Problems solved by technology

However, the patent uses statin molecular prodrugs, which need to be hydrolyzed into statins in the body by ester hydrolase to exert their efficacy. into the material, because the material cannot be degraded in the body, it needs to be taken out again

The patent application with the publication number CN101856342A discloses a pravastatin transdermal administration preparation, which mixes pravastatin with a transdermal enhancer, a reservoir matrix composed of synthetic polymers and / or modified cellulose Obtain drug reservoirs and prepare transdermal drug formulations, but the materials used in this dosage form are also basically non-degradable materials, and the sustained drug release time is only 1 to 7 days

Images